Thursday , 21 November 2024

A Study on Evaluation of Risk Profile and Treatment Pattern of Congestive Heart Failure Patients in a Tertiary Care Hospital

Devatha Venkata Sai Pujitha*, P. Pratyusha Ande, Y. Prapurna Chandra
Department of Pharmacy Practice, Ratnam Institute of Pharmacy, Pidathapolur (V&P), Muthukur (M), SPSR Nellore District – 524 346

A b s t r a c t
Heart failure is a complex clinical syndrome that results from a functional or structural heart disorder impairing ventricular filling or ejection of blood to the systemic circulation. It is by definition a failure to meet the systemic demands of circulation. Heart failure remains a highly prevalent disorder worldwide with a high morbidity and mortality rate. The prospective observational study was carried out for a period of 6 months. The study was conducted in cardiology in a tertiary care hospital. A written and informed consent was obtained from the recruited patients. A Total of 135 patients were enrolled in the study. The Leg edema patients were more 40 (29.62 %) as compared to other clinical symptoms.  NYHA Class IV patients were more 59 (43.70%) as compared to other NYHA class patients. 7-8 years duration heart failure patients were more 75 (55.55%) as compared to other heart failure durations. Asthma comrbid patients were more 48 (35.55 ) as compared to other comorbidities. Abnormal ECG patients were more 103 (76.29%) as compared to normal ECG patients. Antiplatelets prescribed patients were more 42 (31.11%) as compared to other prescribed drugs. The incidence of heart failure is slightly higher in males. A combination therapy proves to be more effective than a single drug. A combination of up to 5 drugs are in practice, the most common being Four-drug and Three-drug therapy. The Prescription of generic drugs reduces the patients’ burden making it more affordable and also the chance of survival for long time depends on absence or presence of co-morbidities. 

Keywords: Heart failure, ventricular filling, circulation, co-morbidities, Leg edema, Antiplatelets.

Scroll To Top